Tinea Fasialis

01Pathophysiology

Tinea facialis is caused by dermatophyte fungi that have a unique tropism for keratinized tissue. These organisms produce keratinases, enzymes that digest keratin in the stratum corneum, allowing the fungus to colonize and spread within the superficial epidermis. The infection does not penetrate beyond the keratinized layer in immunocompetent patients because dermatophytes cannot survive at core body temperature and are inhibited by serum transferrin.

The classic annular morphology arises from the centrifugal growth pattern of the dermatophyte. The fungus spreads outward from the initial inoculation site. At the advancing edge, active fungal hyphae invade new keratinocytes, provoking an inflammatory response (type IV hypersensitivity) that produces the raised, erythematous, scaly border. In the center, the immune response has already partially cleared the organism, resulting in central clearing. This is why the lesion looks like a "ring."

When a clinician mistakenly applies topical corticosteroids to the face (a common scenario in vignettes), the anti-inflammatory effect suppresses the host immune response at the border. The result is loss of the typical annular shape, reduction in erythema and scale, and paradoxical expansion of the infection. This altered presentation is called tinea incognito, and it is a frequently tested concept because it demonstrates the consequence of treating without confirming a diagnosis first.

Transmission occurs through direct contact with an infected person (anthropophilic organisms like T. rubrum), contact with infected animals (zoophilic organisms like M. canis from cats and dogs), or rarely through fomites such as shared towels and pillowcases. Zoophilic infections tend to provoke a more intense inflammatory reaction compared to anthropophilic ones due to less host adaptation.

02Classification and Clinical Manifestation

Important distinction to remember: Tinea facialis refers exclusively to dermatophyte infection of the non-bearded facial skin. When the bearded area of adult males is involved, the diagnosis is tinea barbae, which has a different clinical behavior (deeper follicular involvement, boggy plaques resembling a kerion) and always requires systemic therapy.

03Diagnostic Workup

The workup for tinea facialis begins with the KOH preparation, which is the best initial test. To perform this, the clinician scrapes scale from the active, raised border of the lesion (not the center, which has already cleared) using a scalpel blade, places it on a slide with 10% to 20% potassium hydroxide, and examines it under light microscopy. KOH dissolves the keratinocytes while leaving the fungal cell wall intact, revealing septate, branching hyphae. This bedside test gives results in minutes and drives the immediate treatment decision.

If the KOH preparation is positive, many clinicians will start treatment without waiting for culture. However, the fungal culture on Sabouraud dextrose agar remains the gold standard because it identifies the exact dermatophyte species, which is relevant for epidemiological purposes (tracing the source of infection, such as an infected household pet with M. canis). The drawback is the 2 to 4 week incubation time, making it impractical for guiding initial treatment.

Wood lamp examination is often mentioned in vignettes as a quick adjunct. The critical point is that it only detects Microsporum species, which produce a blue-green fluorescence due to pteridine metabolites. Since Trichophyton rubrum, the most common dermatophyte overall, does not fluoresce, a negative Wood lamp has very poor negative predictive value. Exam writers test whether you know this limitation.

Skin biopsy with PAS (Periodic Acid-Schiff) stain or GMS (Grocott methenamine silver) stain is reserved for diagnostically challenging cases, particularly when the morphology is atypical (as in tinea incognito or granulomatous variants) and KOH is repeatedly negative. PAS stain highlights fungal elements in magenta against the tissue background.

04Management and Treatment

Step 1: Confirm the diagnosis before treating. This is the single most important management principle and the reason tinea incognito exists. A KOH preparation should be obtained before initiating therapy, particularly for facial lesions where the differential includes lupus, rosacea, and seborrheic dermatitis.

Step 2: Discontinue any topical corticosteroids immediately. If the patient has been applying a steroid cream (a common scenario in exam vignettes), stopping it is the next best step. Patients should be counseled that the lesion may temporarily appear worse once the steroid is withdrawn, because the previously suppressed inflammatory response will rebound.

Step 3: Initiate antifungal therapy based on disease extent. For localized tinea facialis (one or a few small lesions), topical terbinafine 1% cream applied once to twice daily for a minimum of 2 weeks (and ideally continued for 1 week after clinical resolution) is first-line. Terbinafine is preferred because it is fungicidal (it kills the organism by inhibiting squalene epoxidase, leading to toxic squalene accumulation in the fungal cell membrane), whereas azoles are fungistatic (they inhibit lanosterol 14-alpha-demethylase, blocking ergosterol synthesis but not killing the organism outright). This distinction is tested.

For extensive disease, involvement of vellus hair follicles (Majocchi granuloma), immunosuppressed patients, or failure of topical therapy, oral terbinafine 250 mg daily for 2 to 4 weeks is the preferred systemic agent. Baseline liver function tests should be checked. Oral itraconazole (200 mg daily for 1 to 2 weeks) is an alternative, but the test writer expects you to know its contraindication in congestive heart failure (negative inotropic effect) and its extensive CYP3A4 drug interactions. Oral fluconazole at 150 to 200 mg once weekly is another option and is sometimes favored for adherence.

Griseofulvin remains relevant for pediatric dermatophytosis and for tinea capitis, but it requires a longer treatment course (4 to 6 weeks), must be taken with a fatty meal for adequate absorption, and is absolutely contraindicated in pregnancy due to teratogenicity.

Step 4: Patient education and source control. Examine household contacts and pets for fungal infection. For zoophilic sources (M. canis), the infected animal must be treated by a veterinarian to prevent reinfection. Advise patients to avoid sharing towels, pillowcases, and facial products.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get tinea facialis questions wrong is by failing to recognize tinea incognito. The classic vignette presents a patient who was given a topical corticosteroid for a "rash on the face" that initially improved (because the steroid suppressed inflammation) but then worsened or spread. The lesion no longer looks like a classic ring. The student, anchored by the atypical morphology, selects contact dermatitis or eczema instead of recognizing the modified fungal infection. The next best step in that scenario is always to stop the steroid and perform a KOH preparation.

A second common trap involves the Wood lamp. Students often select "Wood lamp examination" as the best initial diagnostic test. Remember that only Microsporum species fluoresce, and the most common dermatophytes causing tinea facialis (T. rubrum, T. mentagrophytes) will not. The best initial test is always the KOH preparation.

A third pitfall is confusing tinea facialis with discoid lupus. Both produce annular, scaly facial plaques. The discriminator is that lupus produces adherent, follicular plugging scale with eventual scarring and dyspigmentation, while tinea produces a fine trailing scale at the active border with no scarring. When in doubt, the vignette will embed a detail like "KOH shows branching hyphae" or "biopsy shows interface dermatitis" to settle the diagnosis.

Finally, students sometimes choose griseofulvin as first-line for a non-pregnant adult with limited facial tinea. Griseofulvin is not first-line for tinea facialis in adults. Topical terbinafine is the initial approach for limited disease, and oral terbinafine is preferred for extensive disease. Griseofulvin remains the classic choice for tinea capitis in children, but that is a different clinical context.

The core competency being tested with tinea facialis is the ability to recognize a common infection in an uncommon or modified presentation, correctly sequence the diagnostic workup (KOH first, culture for confirmation), and avoid the trap of empiric corticosteroid therapy on the face without a confirmed diagnosis.